natgillin/translations-raw huggingface dataset:
A compound according to any one of claims 1 to 8 for use in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, amyotrophic lateral sclerosis, stroke, transient ischemic attack or uveitis. 
Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u liječenju ili profilaksi sljedećih stanja: bol, ateroskleroza, makularna degeneracija povezana sa starošću, dijabetska retinopatija, glaukom, okluzija retinalne vene, retinopatija kod prerano rođene djece, okularni ishemijski sindrom, geografska atrofija, dijabetes melitus, upala, upalna bolest crijeva, ishemijsko-reperfuzijska ozljeda, akutno zatajenje jetre, fibroza jetre, fibroza pluća, fibroza bubrega, sustavna fibroza, akutno odbacivanje alogenskih presadaka, kronična alogenska nefropatija, dijabetska nefropatija, glomerulonefropatija, kardiomiopatija, zatajenje srca, ishemija miokarda, infarkt miokarda, sustavna skleroza, termalna ozljeda, opekotina, hipertrofični ožiljci, keloidi, gingivitis pireksija, ciroza jetre ili tumori jetre, regulacija koštane mase, neurodegeneracija, amiotrofna lateralna skleroza, moždani udar, prolazni ishemijski napad ili uveitis.
capable of promoting ADCP measured in the presence of CD14 pos and/or CD11b pos blood mononuclear cells, wherein the molecule comprises the sequence selected from the group SEQ ID NO: 8, 10-15, and 18-20, optionally with the additional I332E as defined by the EU numbering system; 
sposobna pokrenuti ADCP koji se mjeri u prisutnosti CD14 pos i/ili CD11b pos mononuklearnih stanica krvi, pri čemu molekula sadrži sekvencu koja je odabrana iz skupine SEQ ID NO: 8, 10-15, i 18-20, proizvoljno s dodatnim I332E kako se definira prema EU sustavu obilježavanja.
the additional substitution I332E as defined by the EU numbering system; or 
dodatnu supstituciju I332E kako se definira prema EU sustavu obilježavanja; ili
capable of binding an Fcγ receptor with comparable or greater affinity than a wild-type IgG2 Fc-domain; or 
sposobna vezati se za Fcγ receptor s usporedivim ili većim afinitetom nego za Fc domenu IgG2 divljeg tipa; ili
capable of binding an Fcγ receptor with comparable or greater affinity than a wild-type IgG1 Fc-domain. 
sposobna vezati se za Fcγ receptor s usporedivim ili većim afinitetom nego za Fc domenu IgG1 divljeg tipa.
An isolated binding molecule which is a recombinant polypeptide comprising: (i) a binding domain capable of binding a target molecule on or bound to a cell, and (ii) an IgG1 Fc region, wherein residues 214 to 238, defined by the EU numbering system, comprise a sequence selected from SEQ ID NO: 4 and 5, with G236 deleted; characterized in that the binding molecule is capable of binding the target molecule on a target cell and the molecule produces measurable complement dependent lysis, or cell mediated destruction of the target cell in the presence of the requisite effector cell type. 
Izolirana vezujuća molekula koja je rekombinantni polipeptid koji obuhvaća: (i) vezujuću domenu koja može vezati ciljanu molekulu koja je na stanici ili koja je vezana za stanicu, te (ii) Fc regiju IgG1, pri čemu ostatci 214 do 238 kako je definirano prema EU sustavu obilježavanja, sadrže sekvencu koja se bira iz SEQ ID NO: 4 i 5, s G236 koji je izbrisan; naznačena time da vezujuća molekula može vezati ciljanu molekulu na ciljanoj stanici i da molekula proizvodi lizu koja je ovisna od komplementa koji se može izmjeriti, ili stanično posredovano ubijanje ciljnih stanica u prisutnosti potrebnog efektorskog staničnog tipa.
The binding molecule of claim 7(iii), wherein the molecule comprises two or more target binding domains and exhibits avidity. 
Vezujuća molekula prema patentnom zahtjevu 7 (iii), naznačena time da molekula obuhvaća dvije ili više domena za ciljno vezanje i izražava aviditet.
The binding molecule of claim 8, wherein the binding domain comprises a paratope of an antibody that binds to an antigen on a tumor cell or tumor vasculature. 
Vezujuća molekula prema patentnom zahtjevu 8, naznačena time da vezujuća molekula obuhvaća paratop protutijela koje se veže za antigen na tumorskoj stanici ili vaskularnom sustavu tumora.
The pharmaceutical composition of claim 11 for use in a method for treating a disease characterized by the unwanted proliferation or migration of cells, wherein disease is a malignant disease, fibrotic disease or a disease characterized by unwanted angiogenesis. 
Farmaceutski pripravak prema patentnom zahtjevu 11 za uporabu u postupku liječenja bolesti koje su naznačene nepoželjnom proliferacijom ili migracijom stanica, pri čemu je bolest maligna bolest, fibrozna bolest, ili bolest koja je naznačena nepoželjnom angiogenezom.
The hydrated compound according to claim 8 characterized by a substantial peak in the X-ray diffraction spectrum, obtained from an x-ray powder diffractometer equipped with a CuKa source (λ= 1.54060 Å), at diffraction angle 2-theta, of 9.0°, in combination with two or more peaks at diffraction angle 2-theta selected from the group consisting of 5.8°, 8.5°, 9.8°, 11.6°, 11.8°, 17.5°, and 24.2°. 
Hidrat spoja u skladu s patentnim zahtjevom 8, naznačen time što daje jaki maksimum u difrakcijskom spektru rendgenskih zraka, dobivenom na difraktometru rendgenskih zraka na prahu, opremljenom izvorom CuKa (λ = 1,54060 Å), pod difrakcijskim kutem 2θ od 9,0°, u kombinaciji s dva ili više maksimuma, pod difrakcijskim kutem 2θ koji se bira iz skupine koju čine 5,8°, 8,5°, 9,8°, 11,6°, 11,8°, 17,5° i 24,2°.
A compound or pharmaceutically acceptable salt thereof according to claims 1 to 4 for use in the treatment of pain associated with osteoarthritis or rheumatoid arthritis. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi u liječenju boli povezane s osteoartritisom ili reumatoidnim artritisom.
A filter (10) as claimed in claim 1, in which first and second deflectors (100) are provided within the respective first and second ports (96). 
Filter (10) sukladno zahtjevu 1, pri čemu su prvi i drugi deflektori (100) pruženi unutar prvog i drugog ulaza (96).
A filter (10) as claimed in any of the preceding claims, in which the first and second ports (96) are in the form of hollow cylindrical sockets. 
Filter (10) sukladno bilo kojem od prethodnih zahtjeva, pri čemu su prvi i drugi ulazi (96) u obliku šupljih cilindričnih utičnica.
A composition comprising a pharmaceutically acceptable carrier and a glucopyranosyl lipid adjuvant (GLA) for use in a method of treating an allergic condition in a subject; 
Sastav koji sadrži farmaceutski prihvatljivi nosač i glukopiranozilni lipidni adjuvans (GLA) za uporabu u metodi liječenja alergiskog stanja kod subjekta;
wherein said composition is substantially devoid of antigens, and is administered as an adjuvant monotherapy or an adjuvant therapy in combination with a co-adjuvant selected from at least one of toll-like receptor (TLR) agonist, saponin, saponin mimetic, imidazoquinoline immune response modifier, double stem loop immune modifier (dSLIM), alum, plant alkaloid, detergent, cytokine and block copolymer, wherein the GLA has the formula: wherein: 
pri čemu je navedeni sastav potpuno bez antigena i daje se kao adjuvantna monoterapija ili adjuvantna terapija u kombinaciji s koadjuvansom odabranim između najmanje jednog od agonista Tollu sličnih receptora (TLR), saponina, mimetika saponina, imidazokinolinskih modulatora imunog odgovora, matičnog imunomodifikatora dvostruke petlje (dSLIM). alauna, biljnog alkaloida, detergenta, citokina i blokirajućeg kopolimera, pri čemu GLA ima formulu:
The composition for use of any one of claims 1-3, wherein the composition is administered as a monotherapy. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu se sastav daje kao monoterapija.
The composition for use of any one of claims 1-3, wherein the composition further comprises a TLR agonist. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu sastav nadalje sadrži agonista TLR-a.
The composition for use of any one of claims 1-3, wherein the composition further comprises a co-adjvant selected from saponin and saponin mimetic. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu sastav nadalje sadrži koadjuvans odabran između saponina i mimetika saponina.
The composition for use of any one of claims 1-6, wherein the pharmaceutically acceptable carrier comprises calcium phosphate, an oil-in-water emulsion, water-in-oil emulsion, liposome, novasome, niosome or microparticle. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-6, pri čemu farmaceutski prihvatljivi nosač sadrži kalcijev fosfat, emulziju ulja u vodi, emulziju vode u ulju, liposom, novasom, niosom ili mikročesticu.
The composition for use of any one of claims 1-7, wherein the allergic condition is seasonal rhinitis. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-7, pri čemu je alergijsko stanje sezonski rinitis.
The composition for use of any one of claims 1-7, wherein the composition is used in the treatment of an allergy to food products, pollen, mites, cats or stinging insects. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-7, pri čemu se sastav koristi u liječenju alergije na prehrambene proizvode, pelud, grinje, mačke ili kukce koji bodu.
with a compound of Formula IV: wherein R1 is as defined above, in the presence of methyl triflate and of a heterogeneous acid scavenger or 
s tvari formule IV: [image] gdje je R1 kako je prethodno definiran, u prisutnosti metil triflata i heterogenog hvatača kiselina ili
with a compound of Formula V wherein R1 is as defined above, in the presence a heterogeneous acid scavenger. 
s tvari formule V: [image] gdje je R1 kako je prethodno definiran, u prisutnosti heterogenog hvatača kiselina.
Device according to claim 5, wherein a static knife in the form of a double sickle is arranged below the rotating knife. 
Uređaj sukladno zahtjevu 5, naznačen time što je statičan nož u obliku dvostrukog srpa postavljen ispod rotirajućeg noža.
Device according to claim 5, wherein the knives are constructed in a scissors design. 
Uređaj sukladno zahtjevu 5 i 6, naznačen time što su noževi konstruirani poput škara.
Device according to claim 1, wherein the caterpillar chassis has a rising slope at both ends. 
Uređaj sukladno zahtjevu 1, naznačen time što šasija gusjeničara (10) ima uzdignutu kosinu s obje strane.
Device according to claim 1, wherein the floating body is a catamaran or a pontoon, which has its own drive unit. 
Uređaj sukladno zahtjevu 1, naznačen time što je plutajuće tijelo (18) katamaran ili ponton koji ima vlastitu pogonsku jedinicu.
The isolated antibody for use of any one of claims 1 or 2, which is a monoclonal antibody, a recombinant antibody, a human antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof, wherein the antibody fragment preferably is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule. 
Izolirano antitijelo ili fragment antitijela prema patentnom zahtjevu 1 ili 2, naznačeno time što predstavlja monoklonsko antitijelo, poliklonsko antitijelo, rekombinantno antitijelo, humanizirano antitijelo, humano antitijelo, himerno antitijelo, multispecifično antitijelo, ili njihov fragment antitijela, naznačen time što je fragment antitijela poželjno Fab fragment, Fab’ fragment, F(ab’)2 fragment, Fv fragment, di-antitijelo, ili jednolančana molekula antitijela.
or a pharmaceutically acceptable thereof. The compound for use according to any preceding claim, selected from: 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide of formula 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((S)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
Pharmaceutical composition comprising pantoprazole as the active ingredient having the form of a tablet comprising 
Farmaceutski sastav koji obuhvaća pantoprazol kao djelatni sastojak u obliku tablete i obuhvaća sljedeće:
a core comprising the active ingredient, an alkalizing substance, a filler and a disintegrant; 
jezgra koja sadrži djelatni sastojak, tvar za alkalizaciju, punilo i dezintegrator;
an optional water-soluble separating layer; and an enteric coating, characterized in that the enteric coating layer has a thickness of 85 µm to 150 µm and in that the pantoprazole is present in the form of particles having an average particle size within the range of 60 µm to 250 µm, which particles consist of pantoprazole and are obtainable by a process comprising the steps of wetting pantoprazole with water in a high shear mixer, passing the wet pantoprazole through a sieve having a mesh size within the range of 0.8 to 2 mm, and drying the mass in a fluid bed dryer, the order of the sieving and drying step being optional. 
enterička obloga, naznačen time, da sloj enteričke obloge ima debljinu od 85 μm do 150 μm, te time, da je pantoprazol prisutan u obliku čestica koje imaju prosječnu veličinu čestice unutar raspona od 60 μm do 250 μm, pri čemu se te čestice sastoje od pantoprazola i mogu se dobiti putem postupka koji obuhvaća korake vlaženja pantoprazola s vodom u brzoreznoj mješalici, prolaženja vlažnog pantoprazola kroz sito koje ima veličinu otvora mreže unutar raspona od 0,8 do 2 mm, te sušenja smjese u sušilici s fluidiziranim slojem, pri čemu se poredak za korake prosijavanja i sušenja, namješta prema potrebi.
The composition of any one of the preceding claims, wherein the filler is lactose or a sugar alcohol, such as mannitol, sorbitol, maltitol, erythrol, or a mixture of two or more of these components. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da punilo je laktoza ili šećerni alkohol, kao što je manitol, sorbitol, maltitol, eritrol, ili mješavina od dva ili više tih spojeva.
The composition of claim 8, wherein the filler is a mixture of mannitol and sorbitol. 
Sastav prema zahtjevu 8, naznačen time, da punilo je mješavina od manitola i sorbitola.
The composition of any one of claims 8 to 10, wherein the sugar alcohol has an average particle size within the range of 30 µm to 500 µm. 
Sastav prema bilo kojem od zahtjeva 8 do 10, naznačen time, da šećerni alkohol ima prosječnu veličinu čestice unutar raspona od 30 μm do 500 μm.
The composition of any one of the preceding claims, wherein the disintegrant is crospovidone, sodium starch glycolate, croscarmelose sodium, sodium carboxymethyl starch, sodium carboxymethyl cellulose, potassium carboxymethyl cellulose, or a mixture of two or more of these components. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da dezintegrator je krospovidon, natrijev škrobni glikolat, kroskarmeloza-natrij, natrij-karboksimetilni škrob, natrij-karboksimetilna celuloza, kalij-karboksimetilna celuloza, ili mješavina od dva ili više tih spojeva.
The composition of any one of the preceding claims, wherein the core additionally comprises a lubricant selected from stearic acid, a hydrogenated vegetable oil, paraffin or an alkali or alkaline earth stearate, aluminum stearate, sodium stearyl fumarate or a mixture of two or more of these compounds, preferably magnesium or calcium stearate. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da jezgra dodatno obuhvaća lubrikant odabran od stearinske kiseline, hidrogeniziranog biljnog ulja, parafina ili alkalijskog ili zemnoalkalijskog stearata, aluminijevog stearata, natrijevog stearil-fumarata ili mješavine od dva ili više tih spojeva, poželjno magnezijevog ili kalcijevog stearata.
The composition of any one of the preceding claims, wherein the core additionally comprises a binder selected from microcrystalline cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone or a mixtures of two or more of these compounds. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da jezgra dodatno obuhvaća vezivo odabrano od mikrokristalne celuloze, hidroksipropilmetil-celuloze, polivinil-pirolidona ili mješavine od dva ili više tih spojeva.
The composition of any one of the preceding claims, wherein the optional separating layer has a thickness of 20 µm to 120 µm. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da opcijski sloj za odvajanje ima debljinu od 20 μm do 120 μm.
The composition of claim 1 wherein the tablet comprises 20 to 40 mg of pantoprazole in the form of sodium salt hydrate or sodium salt hydrate sesquihydrate. 
Sastav prema zahtjevu 1, naznačen time, da tableta obuhvaća od 20 do 40 mg pantoprazola u obliku hidrata natrijeve soli ili hidrata seskvihidrata natrijeve soli.
The material according to claim 1, characterised in that the paper band (1) is coated with polyolefin in the area of the overlap (3) resulted from overlapping the band and the mesh (2) and in the area of overlap (4) where the package is welded by packaging machine. 
Materijal u skladu s patentnim zahtjevom 1, naznačen time, da je papirna traka (1) obložena s poliolefinom u području preklopa (3) rezultirano preklapanjem trake i mreže (2), a u području preklapanja (4), pri čemu je paket zavaren strojem za pakiranje.
The material according of any of claims 1 - 5, characterised in that continuous bands of paper (1) are joined with mesh bands (2) in such arrangement that these paper bands interchange with these mesh bands. 
Materijal u skladu s bilo kojim od patentnih zahtjeva 1 - 5, naznačen time da je kontinuirana papirna traka (1) spojena s mrežastim trakama (2) u takvom rasporedu da se te papirne trake izmjenjuju s tim mrežastim trakama.
The material according to any of claims 1 - 6, characterised in that the mesh pieces (2) are welded into openings (5) cut out in paper sheets. 
Materijal prema bilo kojem od zahtjeva 1 - 6, naznačen time, da su komadi mreže (2) zavareni u otvore (5) izrezane u listovima papira.
The method according to claim 9, characterised in that in continuous band of paper (1) the openings (5) are cut out and then the pieces of mesh (2) corresponding to these openings are placed on them and welded in the area of overlaps (3). 
Metoda prema zahtjevu 9, naznačena time, da se u kontinuiranim papirnim trakama (1) otvori (5) izrezani i zatim su komadići mreže (2), koji odgovaraju tim otvorima smješteni na njih i zavareni na području preklapanja (3).
X is selected from the series consisting of oxygen, sulfur and (R10)(R11)C; one of the groups R1 and R2 is the group R20-NH- and the other of the groups R1 and R2 is the group (R30)(R31)N-; 
X je odabran iz niza koji čine kisik, sumpor i (R10)(R11)C; jedna od skupina R1 i R2 je skupina R20-NH- i druga od skupina R1 i R2 je skupina (R30)(R31)N-;
is selected from the series consisting of hydrogen, halogen and (C1-C4)-alkyl; 
je odabran iz niza koji čine vodik, halogen i (C1-C4)-alkil;
R4, R5, R6, R7, R8, R9, R10 and R11 are independently of one another selected from the series consisting of hydrogen, fluorine and (C1-C4)-alkyl; 
, R5, R6, R7, R8, R9, R10 i R11 su međusobno neovisno odabrani iz niza koji čine vodik, fluor i (C1-C4)-alkil;
R39, R40, R42, R47, R49, R50 and R51 are independently of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl; 
, R40, R42, R47, R49, R50 i R51 su međusobno neovisno odabrani iz niza koji čine vodik i (C1-C4)-alkil;
is selected from the series consisting of hydrogen, fluorine, chlorine, bromine and (C1-C4)-alkyl; 
je odabran iz niza koji čine vodik, fluor, klor, brom i (C1-C4)-alkil;
, R5, R6, R7, R8, R9, R10 and R11 are independently of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl, with the proviso that at least six of these groups are hydrogen. 
, R5, R6, R7, R8, R9, R10 i R11 su međusobno neovisno odabrani iz niza koji čine vodik i (C1-C4)-alkil, uz uvjet da najmanje šest od tih skupina su vodik.
is selected from the series consisting of cyclopropyl and (C1-C2)-alkyl-O-; 
je odabran iz niza koji čine ciklopropil i (C1-C2)-alkil-O-;
, R40, R42, R47, R49, R50 and R51 are independently of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl; 
, R40, R42, R47, R49, R50 i R51 su međusobno neovisno odabrani iz niza koji čine vodik i (C1-C4)-alkil;
p is selected from the series consisting of 0 and 2, wherein all numbers p are independent of one another; 
p je odabran iz niza koji čine 0 i 2, pri čemu svi brojevi p su međusobno neovisni;
is selected from the series consisting of hydrogen, (C1-C4)-alkyl and cyclopropyl; is hydrogen; 
je odabran iz niza koji čine vodik, (C1-C4)-alkil i ciklopropil; je vodik;
is selected from the series consisting of hydrogen, (C1-C4)-alkyl and cyclopropyl; 
je odabran iz niza koji čine vodik, (C1-C4)-alkil i ciklopropil;
is selected from the series consisting of (C3-C6)-cycloalkyl, phenyl and Het1; 
je odabran iz niza koji čine (C3-C6)-cikloalkil, fenil i Het1;
X is selected from the series consisting of oxygen and (R10)(R11)C; one of the groups R1 and R2 is the group R20-NH- and the other of the groups R1 and R2 is the group (R30)(R31)N-; 
X je odabran iz niza koji čine kisik i (R10)(R11)C; jedna od skupina R1 i R2 je skupina R20-NH- i druga od skupina R1 i R2 je skupina (R30)(R31)N-;
is selected from the series consisting of phenyl and Het1, wherein Het1 is selected from the series consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, furanyl and thiophenyl, which are all bonded via a ring carbon atom, and wherein the phenyl and Het1 are all unsubstituted or substituted by one, two or three identical or different substituents selected from the series consisting of fluorine, chlorine, cyano, (C1-C4)-alkyl and (C1-C4)-alkyl-O-, wherein the alkyl groups can be substituted by one or more fluorine substituents; 
je odabran iz niza koji čine fenil i Het1, pri čemu je Het1 odabran iz niza koji čine piridinil, pirimidinil, pirazinil, piridazinil, pirazolil, imidazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, pirolil, furanil i tiofenil, koji su svi povezani preko ugljikovog atoma u prstenu, i pri čemu su fenil i Het1 svi nesupstituirani ili supstituirani s jednim, dva ili tri jednaka ili različita supstituenta odabrana iz niza koji čine fluor, klor, cijano, (C1-C4)-alkil i (C1-C4)-alkil-O-, pri čemu alkilne skupine mogu biti supstituirane s jednim ili više fluoro supstituenata;
is hydrogen; is selected from the series consisting of hydrogen, (C1-C4)-alkyl and cyclopropyl; 
je vodik; je odabran iz niza koji čine vodik, (C1-C4)-alkil i ciklopropil;
is selected from the series consisting of methyl, ethyl, n-propyl, isopropyl and cyclopropyl; is hydrogen; 
je odabran iz niza koji čine metil, etil, n-propil, izopropil i ciklopropil; je vodik;
is selected from the series consisting of hydrogen, methyl and ethyl; and 
je odabran iz niza koji čine vodik, metil i etil; i
is selected from the series consisting of hydrogen, methyl, ethyl, n-propyl and isopropyl; 
je odabran iz niza koji čine vodik, metil, etil, n-propil i izopropil;
is selected from the series consisting of methyl, ethyl, n-propyl and isopropyl; is hydrogen; 
je odabran iz niza koji čine metil, etil, n-propil i izopropil; je vodik;
is selected from the series consisting of methyl, ethyl, n-propyl and isopropyl; 
je odabran iz niza koji čine metil, etil, n-propil i izopropil;
is selected from the series consisting of methyl, ethyl, isopropyl, cyclopropyl and trifluoromethyl. 
je odabran iz niza koji čine metil, etil, izopropil, ciklopropil i trifluorometil.